about
Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrumsHITlights: a career perspective on heparin-induced thrombocytopeniaHIT paradigms and paradoxes.Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.Immunogenic but effective: the HIT-fondaparinux brain puzzler.Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Critical role for mouse marginal zone B cells in PF4/heparin antibody production.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Ilio-femoral by-pass in a patient with heparin-induced thrombocytopaenia (HIT).Heparin induced thrombocytopenia: review.Progressive thrombocytopenia after cardiac surgery in a 67-year-old man.Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemmaBivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review.Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty.Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.Evidence-based guidance on venous thromboembolism in patients with solid tumoursInhibitors of propagation of coagulation: factors V and X.Promise of factor Xa inhibition in acute coronary syndromes.Autoimmune heparin-induced thrombocytopenia.Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism.Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials
P2860
Q26799395-E5430EEA-4FAC-4CDE-8F5F-2706F58116A1Q26828351-37D392B6-DC26-432E-841A-9169BFCC79C4Q33396313-A5121CC2-7007-484A-B42F-09D49C7B3CD2Q33396967-63F5171D-E6B1-47E2-86E9-AB1332724960Q33397282-BA841F68-5061-4395-AC2C-C937FAFD035CQ33399137-1DB4A8EB-B2EE-45F6-B1AD-4B4F796B1DDEQ33399580-68CD91EB-7288-4950-A58D-48345E12348BQ33406245-1C2D2C2A-731D-43D3-8737-4E7186509DC9Q33406904-496D168C-776C-4F38-9A09-95A0D45643A8Q33407198-76712C84-1622-4F6C-B4BC-44F954D5946BQ33409686-66956992-DCBD-46EE-9C09-1035FCC50554Q33410083-9C503C2C-AE6A-4E63-9EBD-EE4A5A6AD7F8Q33414796-69FEFD14-CB50-4B4D-B3DD-75DDF9DF5709Q33426903-CB53E529-2ACE-447C-AB07-94F54149757CQ33433514-967DA5FD-49C8-477E-B53F-80EE422C4AFDQ33434832-A96B82AC-CEBE-456E-B371-423B819BD619Q33440890-7CB23F67-5BB9-49EB-8056-9534CC5B9EE1Q33763946-E9F3A1F0-2FBB-47E0-9434-DC6057BA6DCAQ37872338-1394DD6C-F0C8-4E5F-8A22-AA3B17F8D3BAQ37955861-739B02CD-2132-4E23-B32B-6BE9A1359D52Q38605630-283F0933-C02A-49F6-8DCB-9F01BEE72558Q47371128-D5B2B81B-BCBD-4262-A9E7-6F6F44BA61D0Q57824209-E6848C50-B0F4-48B9-95E2-9F8E4182BBB5
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fondaparinux: does it cause HIT? Can it treat HIT?
@ast
Fondaparinux: does it cause HIT? Can it treat HIT?
@en
type
label
Fondaparinux: does it cause HIT? Can it treat HIT?
@ast
Fondaparinux: does it cause HIT? Can it treat HIT?
@en
prefLabel
Fondaparinux: does it cause HIT? Can it treat HIT?
@ast
Fondaparinux: does it cause HIT? Can it treat HIT?
@en
P2860
P356
P1476
Fondaparinux: does it cause HIT? Can it treat HIT?
@en
P2860
P304
P356
10.1586/EHM.10.54
P577
2010-10-01T00:00:00Z